EP3953457A4 - Vaccin contre la grippe à large et longue durée - Google Patents

Vaccin contre la grippe à large et longue durée Download PDF

Info

Publication number
EP3953457A4
EP3953457A4 EP20787815.8A EP20787815A EP3953457A4 EP 3953457 A4 EP3953457 A4 EP 3953457A4 EP 20787815 A EP20787815 A EP 20787815A EP 3953457 A4 EP3953457 A4 EP 3953457A4
Authority
EP
European Patent Office
Prior art keywords
lasting
broad
long
influenza vaccine
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20787815.8A
Other languages
German (de)
English (en)
Other versions
EP3953457A1 (fr
Inventor
Scot ROBERTS
Sybil Tasker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Altimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune Inc filed Critical Altimmune Inc
Publication of EP3953457A1 publication Critical patent/EP3953457A1/fr
Publication of EP3953457A4 publication Critical patent/EP3953457A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EP20787815.8A 2019-04-06 2020-04-06 Vaccin contre la grippe à large et longue durée Withdrawn EP3953457A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830442P 2019-04-06 2019-04-06
PCT/US2020/026841 WO2020210149A1 (fr) 2019-04-06 2020-04-06 Vaccin contre la grippe à large et longue durée

Publications (2)

Publication Number Publication Date
EP3953457A1 EP3953457A1 (fr) 2022-02-16
EP3953457A4 true EP3953457A4 (fr) 2023-01-11

Family

ID=72751510

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20787815.8A Withdrawn EP3953457A4 (fr) 2019-04-06 2020-04-06 Vaccin contre la grippe à large et longue durée

Country Status (6)

Country Link
EP (1) EP3953457A4 (fr)
JP (1) JP2022526632A (fr)
KR (1) KR20220036909A (fr)
CN (1) CN114222817A (fr)
CA (1) CA3132697A1 (fr)
WO (1) WO2020210149A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175897A1 (en) * 2005-05-23 2009-07-09 Tang De-Chu C System for rapid production of high-titer and replication-competent adenovirus-free recombinant adenovirus vectors
US20090208531A1 (en) * 2006-02-16 2009-08-20 National Institutes Of Health Office Of Technology Antiviral agents and vaccines against influenza
WO2010044921A2 (fr) * 2008-06-03 2010-04-22 Vaxin Inc. Administration intranasale de ligands liant un récepteur ou de gènes codant pour lesdits ligands dans le cadre d'un schéma thérapeutique visant à atténuer les infections provoquées par des agents pathogènes respiratoires
US20100099745A1 (en) * 2006-10-18 2010-04-22 Suryaprakash Sambhara Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003576A1 (en) * 2004-12-09 2007-01-04 Andrea Gambotto Vaccines for the rapid response to pandemic avian influenza
AU2012216357B2 (en) * 2005-04-11 2014-01-30 Purdue Research Foundation Vaccine against pandemic strains of influenza viruses
BRPI0609362A2 (pt) * 2005-04-11 2010-03-30 Us Gov Health & Human Serv vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CN101822843A (zh) * 2010-01-29 2010-09-08 北京工业大学 高致病性禽流感病毒h5n1-ha基因的优化及其重组腺病毒疫苗
US10183069B2 (en) * 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
EP2758075B1 (fr) * 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
RU2485973C1 (ru) * 2012-02-28 2013-06-27 Общество с ограниченной ответственностью "НТфарма" Рекомбинантная трехвалентная вакцина от гриппа человека
KR20160049010A (ko) * 2013-09-06 2016-05-04 알티뮨 인크. 바이러스 벡터화된 백신을 위한 방법 및 조성물
MX2020010421A (es) * 2018-04-04 2021-01-15 Altimmune Inc Combinaciones de composición de vacunas inductoras de células t y usos de las mismas.
JP2022544414A (ja) * 2019-08-13 2022-10-18 アルティミューン インコーポレーティッド 治療剤の有効性及びその投与の経路
CN114096675A (zh) * 2020-02-14 2022-02-25 艾天穆股份有限公司 冠状病毒免疫原性组合物和其用途
WO2021178844A1 (fr) * 2020-03-05 2021-09-10 Altimmune, Inc Compositions immunogènes anti-zika et anti-flavivirus et leur utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175897A1 (en) * 2005-05-23 2009-07-09 Tang De-Chu C System for rapid production of high-titer and replication-competent adenovirus-free recombinant adenovirus vectors
US20090208531A1 (en) * 2006-02-16 2009-08-20 National Institutes Of Health Office Of Technology Antiviral agents and vaccines against influenza
US20100099745A1 (en) * 2006-10-18 2010-04-22 Suryaprakash Sambhara Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
WO2010044921A2 (fr) * 2008-06-03 2010-04-22 Vaxin Inc. Administration intranasale de ligands liant un récepteur ou de gènes codant pour lesdits ligands dans le cadre d'un schéma thérapeutique visant à atténuer les infections provoquées par des agents pathogènes respiratoires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020210149A1 *
TASKER SYBIL: "2554.Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine", OFID 2018:5 (SUPPL 1), 26 November 2018 (2018-11-26), pages S68 - S68, XP093002170, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253025/> [retrieved on 20221125] *

Also Published As

Publication number Publication date
CA3132697A1 (fr) 2020-10-15
WO2020210149A1 (fr) 2020-10-15
JP2022526632A (ja) 2022-05-25
EP3953457A1 (fr) 2022-02-16
KR20220036909A (ko) 2022-03-23
CN114222817A (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
EP3609534A4 (fr) Vaccin à large spectre contre le virus de la grippe
EP3851120A4 (fr) Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
EP3413926A4 (fr) Vaccination et immunothérapie contre le vih
EP3669891A4 (fr) Adjuvant pour vaccin comprenant un liposome dans lequel est inséré un lipopeptide à titre de principe actif et son utilisation
EP3773710A4 (fr) Combinaisons de compositions vaccinales induisant des lymphocytes t et leurs utilisations
EP3900741A4 (fr) Vaccin à arnsam et procédé de préparation associé
ZA202004538B (en) Influenza virus vaccines and uses thereof
EP3827842A4 (fr) Composition contenant un vaccin contre la grippe
EP3830109A4 (fr) Procédés et compositions de vaccin contre l&#39;alphavirus
EP3746078A4 (fr) Formulations orales et utilisations de celles-ci
EP3402514A4 (fr) Méthodes et compositions pour la vaccination contre le virus de la grippe
EP3897712A4 (fr) Formulations et procédés de vaccin contre les norovirus
EP3856895A4 (fr) Vaccins autologues bihapténisés et leurs utilisations
EP3749356A4 (fr) Composition de vaccin et ses utilisations
EP4070110A4 (fr) Réseaux de grippe et leur utilisation
EP3915978A4 (fr) Dérivé de n-benzyl-n-arylsulfonamide, préparation et utilisation associées
EP3866847A4 (fr) Vaccin antiviral
EP3875110A4 (fr) Protéine gb du cmv modifiée et vaccin contre le cmv la comprenant
EP3817744A4 (fr) Formes d&#39;ivosidénib et compositions pharmaceutiques
IL285618A (en) Adjuvants and vaccine formulations
EP3953457A4 (fr) Vaccin contre la grippe à large et longue durée
EP3897691A4 (fr) Vaccins contenant de l&#39;il-10 et leurs utilisations
EP3866830A4 (fr) Procédés et compositions de polypeptide de vaccin
AU2019902942A0 (en) Vaccination methods and compositions
AU2019903349A0 (en) An alphavirus vaccine and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221209

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/44 20060101ALI20221205BHEP

Ipc: C12N 15/00 20060101ALI20221205BHEP

Ipc: C12N 7/01 20060101ALI20221205BHEP

Ipc: C12N 7/00 20060101AFI20221205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230714